Search results for: 'biologics particle analyst'

Opportunities for chemical, biological, radiological, nuclear, and explosive (CBRNE) threat agent detection systems are being largely driven by increasing threats of terrorist attacks. Chemical threats involve use of harmful and toxic industrial chemicals or materials and release of poisonous gases. Biological threats include premeditated attacks b...

By leveraging quantum mechanics, quantum computers offer a computational system many orders of magnitude greater than classical computers. Instead of bits as in classical computers, the fundamental units in quantum computing are qubits, which can exist in a superposition of states between 0 and 1 simultaneously. While classical computer bits are st...

The COVID-19 pandemic led to the rapid scaling up of production activities in the pharmaceutical industry. An increase in the number of FDA approvals in biologics has further accelerated biopharmaceutical production, particularly in North America and Asia. With a boom in biopharmaceuticals anticipated in the next 5 to 7 years, the demand for single...

23 Oct 2020  |  North America  |  Market Research

Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026

Outsourced Manufacturing of the Complex Third Wave of Biosimilars to Spark New Growth Opportunities

Infographics

×

Key Issues Addressed

In this research service, the Transformational Health team at Frost & Sullivan provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market ...

19 Feb 2021  |  North America  |  Market Research

Regulatory and Infrastructure Reforms in India and China Catalyzing the Asian Specialty Generics Market

High Unmet Needs in Niche Oncology Indications will Drive Future Growth Potential

Infographics

×

Frost & Sullivans Transformational Health team provides critical insights into the Asian specialty generics market with this research service, highlighting growth opportunities, selected countries biopharmaceutical environment, and significant R&D, regulatory, and infrastructure reforms influencing its growth. The report examines similarities and c...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

10 Jan 2018  |  Asia Pacific  |  Market Research

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, o...

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars. Expensive biopharmaceuticals are largely used for life-saving disorders such as cancer and diabetes, the incidence of which is increasing with...

This research service titled “Technological Advancements Enabling Polymer Recycling,” provides information on various recycling technologies and assess the capabilites of each technology. This research service covers different recycling technologies such as mechanical, chemical, biological, and chemical with more emphasis on the emerging technology...